Lyell immunopharma to acquire immpact bio and prioritizes its pipeline to focus on next-generation car t-cell therapies

South san francisco, calif., oct. 24, 2024 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel) announced today that it has entered into a definitive agreement to acquire immpact bio usa inc. (“immpact”), a privately-owned clinical-stage biotechnology company. immpact's lead program, impt-314, is a cd19/20-targeting chimeric antigen receptor (car) t-cell product candidate that lyell will continue to develop for hematologic malignancies, including large b-cell lymphoma. impt-314 was designed to outperform the efficacy of approved cd19 car t-cell therapies via a dual-targeting car t-cell design and to improve car t-cell persistence by enriching for naÏve and central memory t cells during manufacturing. the acquisition of immpact is expected to significantly strengthen lyell's clinical-stage pipeline of next- generation car t-cell therapies and complement its suite of proprietary technologies designed to generate longer-lasting, functional t cells to achieve more durable outcomes for patients with solid tumors and hematologic malignancies.
CAR Ratings Summary
CAR Quant Ranking